2,216 Shares in ResMed Inc. (NYSE:RMD) Acquired by World Investment Advisors LLC

World Investment Advisors LLC acquired a new position in ResMed Inc. (NYSE:RMD) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,216 shares of the medical equipment provider’s stock, valued at approximately $541,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. True Wealth Design LLC lifted its holdings in ResMed by 2,200.0% during the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 110 shares during the period. Ashton Thomas Securities LLC purchased a new stake in ResMed during the third quarter worth $34,000. Financial Connections Group Inc. purchased a new stake in ResMed during the second quarter worth $37,000. Blue Trust Inc. lifted its holdings in ResMed by 182.7% during the second quarter. Blue Trust Inc. now owns 212 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 137 shares during the period. Finally, Rothschild Investment LLC purchased a new stake in ResMed during the second quarter worth $44,000. Institutional investors own 54.98% of the company’s stock.

Wall Street Analysts Forecast Growth

RMD has been the subject of a number of analyst reports. KeyCorp upped their target price on ResMed from $251.00 to $266.00 and gave the stock an “overweight” rating in a report on Friday, October 25th. Stifel Nicolaus assumed coverage on ResMed in a report on Friday, December 13th. They set a “hold” rating and a $250.00 target price for the company. Royal Bank of Canada increased their price objective on ResMed from $224.00 to $232.00 and gave the company a “sector perform” rating in a report on Friday, October 25th. Baird R W upgraded ResMed to a “strong-buy” rating in a report on Tuesday, September 24th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of ResMed in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $227.91.

ResMed Price Performance

NYSE RMD opened at $242.62 on Wednesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.92 and a quick ratio of 1.91. The stock’s fifty day moving average price is $243.05 and its 200 day moving average price is $228.22. ResMed Inc. has a 1 year low of $164.12 and a 1 year high of $260.49. The company has a market cap of $35.62 billion, a price-to-earnings ratio of 32.14, a PEG ratio of 1.73 and a beta of 0.68.

ResMed (NYSE:RMD) last released its earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.03 by $0.17. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The firm had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same period in the prior year, the firm earned $1.64 EPS. The firm’s revenue was up 11.1% on a year-over-year basis. As a group, equities research analysts forecast that ResMed Inc. will post 9.34 earnings per share for the current year.

ResMed Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, December 12th. Shareholders of record on Thursday, November 7th were given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 0.87%. The ex-dividend date was Thursday, November 7th. ResMed’s dividend payout ratio is currently 28.08%.

Insiders Place Their Bets

In other ResMed news, CFO Brett Sandercock sold 1,000 shares of the stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $233.47, for a total transaction of $233,470.00. Following the sale, the chief financial officer now directly owns 95,812 shares of the company’s stock, valued at approximately $22,369,227.64. This trade represents a 1.03 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael J. Farrell sold 14,683 shares of the stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $231.91, for a total value of $3,405,134.53. Following the sale, the chief executive officer now directly owns 464,169 shares in the company, valued at $107,645,432.79. This represents a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 47,725 shares of company stock valued at $11,253,448. Company insiders own 0.71% of the company’s stock.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.